Table 1 BsAb monotherapies for B-cell lymphoma
BsAbs | Phase | Settings | N | Median number of prior lines of therapy | Number of treatment cycles | Median follow up (m) | ORR (%) | CR (%) | Median DOR (m) | Median DOCR (m) | Median PFS(m) | CRS Grade ≥ 3 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mosunetuzumab [1] | II | RRFL | 90 | 3(2–10) | with a CR: Mosun was stopped after 8 cycles; PR or SD: Mosun could be continued for up to 17 cycles | 27 | 77.8 | 70.0 | NR | NR | NR | 2.22 |
Odronextamab [2] | II | RRFL | 96 | 3(2–13) | until PD or unacceptable toxicity | 17.3 | 81 | 75 | 18.2 | 18.2 | 20.2 | 0 |
Odronextamab [3] | II | RR DLBCL | 121 | 2(2–8) | until PD or unacceptable toxicity | 17.1 | 53 | 37 | - | NR | - | 0 |
Epcoritamab [4] | II | RR DLBCL | 157 | 3(2–11) | until PD or unacceptable toxicity | 10.7 | 63 | 39 | 12.0 | NR | - | 2.5% |
Mosunetuzumab [5] | I/II | ND DLBCL | 53 | - | with a CR: Mosun was stopped after 8 cycles; with a PR or SD: Mosun could be continued for up to 17 cycles | 23.3 | 56 | 43 | - | 15.8 | 12 m PFS 39% | 0 |